REGN17092 / Regeneron - LARVOL DELTA

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of REGN17092, an YTE modified Anti-SARS-COV-2 (COVID-19) Monoclonal Antibody in Adult Healthy Volunteers (IDWeek 2025) - No abstract available

Clinical • P1 data • PK/PD data • Infectious Disease • Novel Coronavirus Disease

A Trial to Learn if Different Doses of REGN17092 Are Safe in Healthy Adults (clinicaltrials.gov) - P1 | N=40 | Completed | Sponsor: Regeneron Pharmaceuticals | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

An update on the anti-Spike monoclonal antibody pipeline for SARS-CoV-2. (PubMed, Clin Microbiol Infect) - "The anti-Spike monoclonal antibody clinical pipeline is currently limited to few agents (most being single antibodies) with unknown efficacy against the dominant JN.1 sublineage. The field of antibody-based therapies requires boosting by both manufacturers and institutions."

Journal • Review • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Trial to Learn if Different Doses of REGN17092 Are Safe in Healthy Adults (clinicaltrials.gov) - P1 | N=40 | Active, not recruiting | Sponsor: Regeneron Pharmaceuticals | Recruiting ➔ Active, not recruiting | N=128 ➔ 40

Enrollment change • Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Trial to Learn if Different Doses of REGN17092 Are Safe in Healthy Adults (clinicaltrials.gov) - P1 | N=128 | Recruiting | Sponsor: Regeneron Pharmaceuticals | Not yet recruiting ➔ Recruiting | Trial completion date: Nov 2024 ➔ Apr 2025 | Trial primary completion date: Nov 2024 ➔ Apr 2025

Enrollment open • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Trial to Learn if Different Doses of REGN17092 Are Safe in Healthy Adults (clinicaltrials.gov) - P1 | N=128 | Not yet recruiting | Sponsor: Regeneron Pharmaceuticals

New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases